Neurogene closed at $27.58 on Nov 4, up 3.41%, 35.6% below its 52-week closing high. Volume of 209.1K shares was 0.58× its 20-day average (below normal).
Split-adjusted performance: +8.4% over one month, -14.7% over six months, -11.2% over one year.
Short interest was 5.1M shares at the Oct 15 settlement, up 2.4% from the prior report (39.6% of float, 14.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NGNENeurogene | $27.58 | +3.41% | −14.7% | — | — | — | $551.9M | |
| PBYIPUMA BIOTECHNOLOGY | $10.69 | +4.60% | +43.5% | +7.8% | 14.5% | 20.7 | $551.8M | Compare |
| CLYMClimb Bio | $9.33 | −4.31% | −23.6% | — | — | — | $535.9M | Compare |
| OVIDOvid Therapeutics | $2.74 | +14.17% | −1.4% | −88.3% | −2047.6% | — | $535.1M | Compare |
| ACRSAclaris Therapeutics | $3.68 | −1.60% | −23.0% | −8.3% | −1320.1% | — | $570.3M | Compare |
| DMACDiaMedica Therapeutics | $10.77 | +7.70% | +65.2% | — | — | — | $580.8M | Compare |
| CAPRCapricor Therapeutics | $8.92 | +8.25% | −74.1% | — | — | — | $518.6M | Compare |
| BCAXBicara Therapeutics | $8.89 | −0.78% | −62.6% | — | — | — | $588.3M | Compare |
| STTKShattuck Labs | $5.15 | −5.85% | −22.9% | — | — | — | $516.9M | Compare |
No recent articles focused on Neurogene. 1 articles mention it in passing.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
